The role of PTEN in pancreatic ductal adenocarcinoma

Michael J. Mendoza,Bangyan L. Stiles,Yuval Dor,Ben Z. Stanger,Douglas A. Melton,Hong Wu

IF: 11.2

2005-01-01

Cancer Research

Abstract:1101 Pancreatic Ductal Adenocarcinoma (PDA) is the fourth most common cause of cancer related deaths annually and has a dismal five-year survival of only 5%. Presently little is known about PDA pathogenesis, though activated K-Ras is found in greater than 90% of cases. It is known that K-Ras can activate PI3K by binding to the p110 catalytic subunit and 32% of human pancreatic tumor samples have been shown to have increased Akt2 activity, a downstream signaling molecule of the PI3K pathway. More recently, Pten expression was shown to be absent or significantly decreased in 71% of human PDA samples. In order to further delineate the pathogenetic pathways involved in PDA, we are studying the involvement of the PI3K-Akt pathway utilizing pancreatic cancer cell lines and tissue specific mouse models. We demonstrated reduced PTEN levels in poorly differentiated pancreatic cancer cell lines by western blot analysis. Moreover, in vivo studies reveal that Pdx1-Cre, PtenLox/Lox mice develop Pancreatic Intraepithelial Neoplastic (PanIN) lesions as early as 8 weeks of age. We plan to further evaluate the differential PTEN levels in various cells lines and evaluate downstream effectors that are mediating increased Akt activity. Lastly, we are evaluating the role of PTEN in PDA development and the cellular origin of PanIN lesions using a pancreas specific PTEN knockout containing a LacZ reporter.